Imprimis Pharmaceuticals, a maker of compounded drugs, will begin selling a $1 version of a drug similar to Daraprim, the medication used for AIDS and cancer whose price was famously hiked by the vilified Martin Shkreli, CEO of Turing Pharmaceuticals. A compounded drug (the combination of two or more drugs to creates a tailored medication for individual patients) can offer a cheaper alternative, similar to generics. After his public relations disaster, Shkreli eventually said he would lower the price of Daraprim, but provided few specific details for that plan. Also, what else was he going to do? He'd already been embarrassed by an ex-girlfriend, embarrassed by a stranger on Tinder, and embarrassed by Bernie Sanders. This recent tweet by Martin pretty much sums it up:
The CEO of Imprimis plans to implement the compounding strategy with other drugs that have experienced extreme price increases:
We are looking at all of these cases where the sole-source generic companies are jacking the price way up. There'll be many more of these.
This means there is actually a pharmaceutical company that is intentionally doing good instead of evil. And, in a fun twist of irony, the same free market regulations that enabled Shkreli to jack the price also allow for a competitor to swoop in and eat his lunch. Capitalism is a harsh mistress! Hopefully, the solution put forward by Imprimis enables healthcare providers to administer more affordable treatments for patients on the road to recovery.